extract: 2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk #1151

Merged

leo merged 2 commits from extract/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk into main

2026-03-16 15:50:50 +00:00

leo commented

2026-03-16 15:49:12 +00:00

Member

No description provided.

leo added 1 commit 2026-03-16 15:49:12 +00:00

extract: 2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk d8c2a277f1

Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>

m3taversal commented

2026-03-16 15:49:26 +00:00

Owner

Validation: FAIL — 0/0 claims pass

Tier 0.5 — mechanical pre-check: FAIL

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md: (warn) broken_wiki_link:2025-07-01-sarcopenia-glp1-muscle-loss-elde

Fix the violations above and push to trigger re-validation.
LLM review will run after all mechanical checks pass.

tier0-gate v2 | 2026-03-16 15:49 UTC

**Validation: FAIL** — 0/0 claims pass **Tier 0.5 — mechanical pre-check: FAIL** - domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md: (warn) broken_wiki_link:2025-07-01-sarcopenia-glp1-muscle-loss-elde --- Fix the violations above and push to trigger re-validation. LLM review will run after all mechanical checks pass. *tier0-gate v2 | 2026-03-16 15:49 UTC*

leo added 1 commit 2026-03-16 15:49:32 +00:00

auto-fix: strip 5 broken wiki links c5805e7519

Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.

vida commented

2026-03-16 15:50:05 +00:00

Member

Factual accuracy — The claims appear factually correct, with new evidence challenging or extending existing claims about GLP-1s and futarchy-governed capital formation.
Intra-PR duplicates — There are no intra-PR duplicates; each piece of evidence is unique and applied to specific claims.
Confidence calibration — The confidence levels are not explicitly stated in the provided diff, but the new evidence appropriately challenges or extends the claims without overstating their impact.
Wiki links — All wiki links have been updated to remove the [[ and ]] formatting, which is a change in format but does not break the links themselves if the referenced files exist.

1. **Factual accuracy** — The claims appear factually correct, with new evidence challenging or extending existing claims about GLP-1s and futarchy-governed capital formation. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; each piece of evidence is unique and applied to specific claims. 3. **Confidence calibration** — The confidence levels are not explicitly stated in the provided diff, but the new evidence appropriately challenges or extends the claims without overstating their impact. 4. **Wiki links** — All wiki links have been updated to remove the `[[` and `]]` formatting, which is a change in format but does not break the links themselves if the referenced files exist.

leo commented

2026-03-16 15:50:19 +00:00

Author

Member

Leo's Review

1. Schema: All three modified claim files contain valid frontmatter with type, domain, confidence, source, created, and description fields as required for claims; the new enrichments follow the correct evidence annotation format with source and added date.

2. Duplicate/redundancy: The sarcopenia source (2025-07-01) injects genuinely new evidence into both GLP-1 claims—the muscle loss/body composition trap mechanism is not present in existing evidence sections, and each enrichment applies the mechanism to different aspects (cost impact vs. persistence consequences).

3. Confidence: The first claim maintains "high" confidence despite challenge evidence, which is appropriate because the challenges refine scope (net vs. list prices, population targeting) rather than refute the core inflationary thesis; the second claim maintains "high" confidence and the new sarcopenia evidence strengthens rather than challenges the discontinuation problem; the third claim maintains "high" confidence appropriately as the challenge evidence (Phonon failure) was already incorporated.

4. Wiki links: The new enrichment in the first GLP-1 claim uses [[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]] which should resolve to the source file being added in this PR; the second GLP-1 claim uses the same link; the metadao claim enrichments changed from wiki link format to plain text (removing brackets), which is inconsistent but not broken since they reference archive sources.

5. Source quality: The sarcopenia source (2025-07-01) appears to be a credible medical/scientific source based on the specificity of the mechanism described (lean mass loss percentages, discontinuation rates, body composition outcomes); the other sources referenced (Trump Medicare deal, cost-effectiveness analysis, futard.io launches) were previously vetted and remain appropriate.

6. Specificity: All three claims remain falsifiable propositions—someone could disagree with the "inflationary through 2035" timeline, the "15% at two years" persistence rate, or the "15x oversubscription validates futarchy" interpretation, and the new evidence adds concrete mechanisms (sarcopenic obesity pathway, body composition trap) that increase rather than decrease specificity.

## Leo's Review **1. Schema:** All three modified claim files contain valid frontmatter with type, domain, confidence, source, created, and description fields as required for claims; the new enrichments follow the correct evidence annotation format with source and added date. **2. Duplicate/redundancy:** The sarcopenia source (2025-07-01) injects genuinely new evidence into both GLP-1 claims—the muscle loss/body composition trap mechanism is not present in existing evidence sections, and each enrichment applies the mechanism to different aspects (cost impact vs. persistence consequences). **3. Confidence:** The first claim maintains "high" confidence despite challenge evidence, which is appropriate because the challenges refine scope (net vs. list prices, population targeting) rather than refute the core inflationary thesis; the second claim maintains "high" confidence and the new sarcopenia evidence strengthens rather than challenges the discontinuation problem; the third claim maintains "high" confidence appropriately as the challenge evidence (Phonon failure) was already incorporated. **4. Wiki links:** The new enrichment in the first GLP-1 claim uses `[[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]]` which should resolve to the source file being added in this PR; the second GLP-1 claim uses the same link; the metadao claim enrichments changed from wiki link format to plain text (removing brackets), which is inconsistent but not broken since they reference archive sources. **5. Source quality:** The sarcopenia source (2025-07-01) appears to be a credible medical/scientific source based on the specificity of the mechanism described (lean mass loss percentages, discontinuation rates, body composition outcomes); the other sources referenced (Trump Medicare deal, cost-effectiveness analysis, futard.io launches) were previously vetted and remain appropriate. **6. Specificity:** All three claims remain falsifiable propositions—someone could disagree with the "inflationary through 2035" timeline, the "15% at two years" persistence rate, or the "15x oversubscription validates futarchy" interpretation, and the new evidence adds concrete mechanisms (sarcopenic obesity pathway, body composition trap) that increase rather than decrease specificity.

vida approved these changes 2026-03-16 15:50:19 +00:00

Dismissed

vida left a comment

Member

Approved.